4.5 Review

Control of articular synovitis for bone and cartilage regeneration in rheumatoid arthritis

Journal

INFLAMMATION AND REGENERATION
Volume 38, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s41232-018-0064-y

Keywords

Rheumatoid arthritis; Joint destruction; Synovitis; Articular cartilage; Regeneration

Funding

  1. pharmaceutical company (Chugai Pharmaceutical Co. Ltd)
  2. pharmaceutical company (UCB Japan Co. Ltd)
  3. pharmaceutical company (AYUMI Pharmaceutical Co.)
  4. Daiichi Sankyo Co. Ltd.
  5. Bristol-Myers
  6. Astellas
  7. Eli Lily
  8. Daiichi-Sankyo
  9. Abbvie
  10. Pfizer
  11. Taisho-Toyama
  12. pharmaceutical company (Mitsubishi Tanabe Pharma Co.)
  13. Nagahama City, Shiga, Japan

Ask authors/readers for more resources

Background: Rheumatoid arthritis is an autoimmune inflammatory disease, the specific feature of which is progressive joint destruction induced by synovitis. The universal consensus is that alleviation of the synovitis is essential to prevent joint destruction and achieve clinical remission. Main text: We have shown that not only achieving but also maintaining remission is crucial to prevent the progression of joint destruction. Although regeneration of the damaged joints is considered very rare, accumulating evidence shows that it actually occurs in routine clinical practice as a result of strong inhibition of synovitis using highly potent medications. Oral and intravenous medications affect the whole body, but to promote joint regeneration in a particular joint, two potent options are intra-articular steroid injection and synovectomy. Conclusion: In situations where strong inhibition of synovitis combined with self-regeneration cannot repair severe joint destruction, regenerative medicine may in the future play a crucial role in the regeneration of damaged joints.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available